GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chemomab Therapeutics Ltd (STU:2QV0) » Definitions » Float Percentage Of Total Shares Outstanding

Chemomab Therapeutics (STU:2QV0) Float Percentage Of Total Shares Outstanding : 0.00% (As of May. 02, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Chemomab Therapeutics Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Chemomab Therapeutics's float shares is 0.00 Mil. Chemomab Therapeutics's total shares outstanding is 18.86 Mil. Chemomab Therapeutics's float percentage of total shares outstanding is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Chemomab Therapeutics's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Chemomab Therapeutics's Institutional Ownership is 4.86%.

Chemomab Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Chemomab Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=0.00/18.86
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chemomab Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chemomab Therapeutics Ltd (STU:2QV0) » Definitions » Float Percentage Of Total Shares Outstanding
Comparable Companies
OVID PULM CVM MLEC CARA CDIO TENX NRSN CLGN IGC VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
CMMB:USA 2QV0:Germany
Address
Kiryat Atidim, Building 7, Tel Aviv, ISR, 6158002
Website
https://www.chemomab.com
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.

Chemomab Therapeutics Headlines

No Headlines